Consistent trends were observed with SRC amplifications in PFS (p = 0.10, HR = 0.69 [0.44–1.07], median PFS wild-type tumours 9.6 months vs mutants 11.1 months) and ORR (p = 0.18, OR = 0.45 [0.14–1.45], ratio ORR wild-type 0.66 vs mutant tumours 0.83). This evidence concerns the gene SRC and neoplasm.